title: [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
abstract: Two patients with chronic myelogenous leukaemia were treated according to an original regimen consisting of the association of alpha-2b interferon, three days a week, plus hydroxyurea during ten months, followed by interferon (same doses) and intermittent high doses of busulphan (50 mg, one dose per month, up to 6 doses). Both patients achieved minor cytogenetic remission in the first stage (50% and 80% of Ph'-positive metaphases, respectively). Upon concluding the second phase, one patient attained complete cytogenetic remission and the other showed major cytogenetic remission (3% Ph'-positive metaphases); complete remission was achieved in the second patient after 4 more doses of busulphan. Both patients remain in complete cytogenetic remission after 4 and 2 years, respectively, with three weekly doses of interferon as maintenance therapy. This protocol is quite different to others applied so far and might represent a good choice for patients unsuitable for bone marrow transplantation.
authors.affiliation: Servicio de Hematología, Hospital Universitario Puerta del Mar Cádiz.
authors.forename: D
authors.initials: D
authors.lastname: Armenta
authors.forename: C
authors.initials: C
authors.lastname: Espallargas
authors.forename: A
authors.initials: A
authors.lastname: Paz
authors.forename: J
authors.initials: J
authors.lastname: Rodríguez Martorel
authors.forename: R
authors.initials: R
authors.lastname: Ladines
authors.forename: C
authors.initials: C
authors.lastname: Alvarez
authors.forename: J
authors.initials: J
authors.lastname: Román
authors.forename: P
authors.initials: P
authors.lastname: Andrés
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002066:Busulfan / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002066:Busulfan; D006918:Hydroxyurea
vernacular_title: Remisión citogenética completa de la leucemia mieloide crónica con interferón alfa-2b a bajas dosis y busulfán a altas dosis mensuales.